News & Updates

Patients with inflammatory bowel disease (IBD) report that the COVID-19 pandemic is a “major concern” for them, reveals a study, noting that the cumulative prevalence is low in this cohort. At-risk patients must be identified and counseled individually.

The Pfizer-BNT162b2 vaccine for the coronavirus disease 2019 (COVID-19) effectively reduces the risk of serious outcomes and hospitalization in patients with inflammatory bowel diseases (IBD), though with slight variance in effectivity with respect to ongoing medications, reports a Qatar study presented at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

Most patients with community-acquired pneumonia go untested for influenza even during flu season, which is unfortunate since a positive test result facilitates antiviral therapy, and early treatment leads to lower mortality, according to a study.

Thermal water vapour therapy that consists of a single injection per prostate lobe for benign prostatic hyperplasia (BPH) is both effective and safe, yielding similar improvements in lower urinary tract symptoms and quality of life when compared with a traditional approach that employed variable number of injections by prostate volume, as shown in a study.

Treatment with the combination therapy of casirivimab and imdevimab prevents the risk of developing symptomatic COVID-19 among asymptomatic individuals with SARS-CoV-2 infection in a household close-contact setting, according to a recent study.

In women with gestational diabetes (GDM) and obesity, gestational weight gain (GWG) appears to influence pregnancy outcomes, according to data presented at SMFM 2022.

Recent findings by the Multimodal Treatment Study of ADHD (attention deficit hyperactivity disorder; MTA) question the belief that nearly half of the children with ADHD outgrow the disorder when they reach adulthood. In majority of the cases, symptoms come and go between childhood and young adulthood.